Physician profile
Joel Selter
NPI 1174526016
$84,326.45
in general payments reported to CMS, 2019-2025
32 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,310 · 2021: $14K · 2022: $13K · 2023: $9,713 · 2024: $17K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $7,056 · Consulting Fee: $1,815 · Travel and Lodging: $1,123 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,925.00 |
| Food and Beverage | $7,055.65 |
| Consulting Fee | $1,815.00 |
| Travel and Lodging | $1,123.13 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $71,766.67 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Grifols USA, LLC | $3,147.02 | 2019-2025 | Xembify |
| Csl Behring | $1,349.39 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,346.58 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $798.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $697.69 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $641.01 | 2022-2025 | Cuvitru, Hyqvia, Takhzyro |
| Biocryst US Sales Co., LLC | $583.34 | 2021-2025 | Orladeyo |
| Pfizer INC. | $542.88 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $533.42 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $332.24 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $327.42 | 2019-2025 | Ruconest |
| Kaleo, INC. | $324.65 | 2020-2024 | Auvi-Q |
| Amgen INC. | $287.89 | 2021-2025 | Tezspire |
| Incyte Corporation | $196.05 | 2021-2025 | Opzelura, Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $162.80 | 2019-2025 | |
| Next Science LLC | $149.90 | 2023 | Surgx, Blastx, Xperience |
| Alk-Abello, INC | $147.60 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Ionis Pharmaceuticals, INC. | $144.73 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $142.40 | 2023-2024 | Ayvakit |
| Covis Pharma Gmbh | $137.99 | 2019-2023 | |
| Cycle Pharmaceuticals INC | $120.54 | 2024-2025 | Sajazir |
| Ars Pharmaceuticals Operations, INC. | $91.55 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.75 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $60.32 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $40.38 | 2019-2020 | |
| Shire North American Group INC | $37.77 | 2019 | |
| Aimmune Therapeutics, INC. | $23.15 | 2022 | |
| Galderma Laboratories, L.P. | $21.86 | 2025 | Nemluvio |
| Viatris Specialty LLC | $15.77 | 2025 | Yupelri |
| Azurity Pharmaceuticals, INC. | $15.62 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Selter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.